Last reviewed · How we verify
C=Inhaled Alprazolam 1 m
Alprazolam acts as a positive allosteric modulator of the GABAA receptor, enhancing the inhibitory effects of GABA in the central nervous system.
Alprazolam acts as a positive allosteric modulator of the GABAA receptor, enhancing the inhibitory effects of GABA in the central nervous system. Used for Anxiety disorders, Panic disorders.
At a glance
| Generic name | C=Inhaled Alprazolam 1 m |
|---|---|
| Sponsor | Alexza Pharmaceuticals, Inc. |
| Drug class | benzodiazepine |
| Target | GABAA receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
By binding to specific sites on the GABAA receptor, alprazolam potentiates the action of GABA, leading to increased chloride ion influx and hyperpolarization of neurons, which results in sedative, anxiolytic, and anticonvulsant effects.
Approved indications
- Anxiety disorders
- Panic disorders
Common side effects
- Drowsiness
- Dizziness
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- C=Inhaled Alprazolam 1 m CI brief — competitive landscape report
- C=Inhaled Alprazolam 1 m updates RSS · CI watch RSS
- Alexza Pharmaceuticals, Inc. portfolio CI